Effect more pronounced in those with more active coronary disease
TUESDAY, Oct. 22 (HealthDay News) -- Influenza vaccination is associated with a lower risk of cardiovascular events among those at high risk of cardiovascular disease, particularly among those with more active coronary disease, according to a review and meta-analysis published in the Oct. 23/30 issue of the Journal of the American Medical Association.
Jacob A. Udell, M.D., M.P.H., from the University of Toronto, and colleagues identified and performed a meta-analysis of five published and one unpublished randomized clinical trials involving 6,735 patients at high risk of cardiovascular disease and comparing influenza vaccine versus placebo or control. The mean follow-up time was 7.9 months.
The researchers found that influenza vaccination was associated with a significantly lower risk of composite cardiovascular events (2.9 versus 4.7 percent; relative risk 0.64). The lower risk was largely confined to patients with a recent history of acute coronary syndrome (within one year of randomization; relative risk, 0.45; P < 0.001) compared to those without a recent history of acute coronary syndrome (relative risk, 0.94; P = 0.81).
"In a meta-analysis of randomized clinical trials, the use of influenza vaccine was associated with a lower risk of major adverse cardiovascular events," Udell and colleagues conclude. "The greatest treatment effect was seen among the highest-risk patients with more active coronary disease."
Several authors disclosed financial relationships with pharmaceutical companies.
Abstract (http://jama.jamanetwork.com/article.aspx?articleid=1758749#Abstract )Full Text (http://jama.jamanetwork.com/article.aspx?articleid=1758749 )Editorial (subscription or payment may be required) (http://jama.jamanetwork.com/article.aspx?articleid=1758725 )